Skip to main content

Advertisement

SpringerLink
Log in

Overexpression of microRNA-100 predicts an unfavorable prognosis in renal cell carcinoma

  • Urology - Original Paper
  • Published:
International Urology and Nephrology Aims and scope Submit manuscript

Abstract

Purpose

Dysregulation of microRNA-100 (miR-100) has been reported to be involved in tumorigenesis and tumor progression of several cancer types. However, its expression patterns in tumors are controversial. The aim of this study was to investigate the expression and clinical significance of miR-100 in renal cell carcinoma (RCC).

Methods

Real-time quantitative PCR was performed to detect the expression levels of miR-100 in 96 paired samples of RCC and adjacent non-cancerous renal tissues. Then, statistical analysis was performed to determine the associations of miR-100 expression with the clinical features and the prognosis of RCCs.

Results

miR-100 expression was significantly higher in RCC tissues compared with adjacent non-cancerous renal tissues (5.3 ± 2.2 vs. 1.9 ± 0.8, P < 0.001). In addition, high miR-100 expression in RCC tissues was significantly associated with advanced tumor T stage (P = 0.005) and grade (P = 0.01), and the presence of metastasis (P = 0.008). Moreover, Kaplan–Meier analysis showed the significant differences in 5-year overall (50.0 vs. 83.3 %, P = 0.006) and tumor-specific survival (58.3 vs. 83.3 %, P = 0.008) for patients with high and low miR-100 expression, respectively. Furthermore, multivariable Cox regression analysis identified high miR-100 expression in RCC tissues as an independent poor prognostic marker of both overall (P = 0.01) and tumor-specific survival (P = 0.02) in patients with RCCs.

Conclusion

Our data offer convincing evidence that miR-100 overexpression strongly associates with advanced tumor progression and unfavorable clinical outcome of patients with RCC. miR-100 expression may be a useful prognostic marker for this disease.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ (2009) Cancer statistics, 2009. CA Cancer J Clin 59:225–249

    Article  PubMed  Google Scholar 

  2. Russo P (2008) Contemporary understanding and management of renal cortical tumors. Urol Clin N Am 35:xiii–xvii

    Article  Google Scholar 

  3. Sejima T, Morizane S, Hinata N, Yao A, Isoyama T, Saito M, Takenaka A (2012) Fas expression in renal cell carcinoma accurately predicts patient survival after radical nephrectomy. Urol Int 88:263–270

    Article  PubMed  CAS  Google Scholar 

  4. Decastro GJ, McKiernan JM (2008) Epidemiology, clinical staging, and presentation of renal cell carcinoma. Urol Clin N Am 35:581–592

    Article  Google Scholar 

  5. Dhote R, Pellicer-Coeuret M, Thiounn N, Debre B, Vidal-Trecan G (2000) Risk factors for adult renal cell carcinoma: a systematic review and implications for prevention. BJU Int 86:20–27

    Article  PubMed  CAS  Google Scholar 

  6. Calin GA, Sevignani C, Dumitru CD (2004) Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci USA 101:2999

    Article  PubMed  CAS  Google Scholar 

  7. Gottardo F, Liu CG, Ferracin M, Calin GA, Fassan M, Bassi P, Sevignani C, Byrne D, Negrini M, Pagano F, Gomella LG, Croce CM, Baffa R (2007) Micro-RNA profiling in kidney and bladder cancers. Urol Oncol 25:387–392

    Article  PubMed  CAS  Google Scholar 

  8. Wu X, Weng L, Li X, Guo C, Pal SK, Jin JM, Li Y, Nelson RA, Mu B, Onami SH, Wu JJ, Ruel NH, Wilczynski SP, Gao H, Covarrubias M, Figlin RA, Weiss LM, Wu H (2012) Identification of a 4-microRNA signature for clear cell renal cell carcinoma metastasis and prognosis. PLoS ONE 7:e35661

    Article  PubMed  CAS  Google Scholar 

  9. Leite KR, Tomiyama A, Reis ST, Sousa-Canavez JM, Sañudo A, Camara-Lopes LH, Srougi M (2011) MicroRNA expression profiles in the progression of prostate cancer-from high-grade prostate intraepithelial neoplasia to metastasis. Urol Oncol (in press)

  10. Feng B, Wang R, Chen LB (2012) MiR-100 resensitizes docetaxel-resistant human lung adenocarcinoma cells (SPC-A1) to docetaxel by targeting Plk1. Cancer Lett 317:184–191

    Article  PubMed  CAS  Google Scholar 

  11. Zheng YS, Zhang H, Zhang XJ, Feng DD, Luo XQ, Zeng CW, Lin KY, Zhou H, Qu LH, Zhang P, Chen YQ (2012) MiR-100 regulates cell differentiation and survival by targeting RBSP3, a phosphatase-like tumor suppressor in acute myeloid leukemia. Oncogene 31:80–92

    Article  PubMed  Google Scholar 

  12. Peng DX, Luo M, Qiu LW, He YL, Wang XF (2012) Prognostic implications of microRNA-100 and its functional roles in human epithelial ovarian cancer. Oncol Rep 27:1238–1244

    PubMed  CAS  Google Scholar 

  13. Oliveira JC, Brassesco MS, Morales AG, Pezuk JA, Fedatto PF, da Silva GN, Scrideli CA, Tone LG (2011) MicroRNA-100 acts as a tumor suppressor in human bladder carcinoma 5637 cells. Asian Pac J Cancer Prev 12:3001–3004

    PubMed  Google Scholar 

  14. Henson BJ, Bhattacharjee S, O’Dee DM, Feingold E, Gollin SM (2009) Decreased expression of miR-125b and miR-100 in oral cancer cells contributes to malignancy. Genes Chromosomes Cancer 48:569–582

    Article  PubMed  CAS  Google Scholar 

  15. Zeng Y, Qu X, Li H, Huang S, Wang S, Xu Q, Lin R, Han Q, Li J, Zhao RC (2012) MicroRNA-100 regulates osteogenic differentiation of human adipose-derived mesenchymal stem cells by targeting BMPR2. FEBS Lett 586:2375–2381

    Article  PubMed  CAS  Google Scholar 

  16. Gebeshuber CA, Martinez J (2012) miR-100 suppresses IGF2 and inhibits breast tumorigenesis by interfering with proliferation and survival signaling. Oncogene (in press)

  17. Muriel López C, Esteban E, Berros JP, Pardo P, Astudillo A, Izquierdo M, Crespo G, Sanmamed M, Fonseca PJ, Martínez-Camblor P (2012) Prognostic factors in patients with advanced renal cell carcinoma. Clin Genitourin Cancer 10:262–270

Download references

Conflict of interest

None.

Author information

Authors and Affiliations

  1. Department of Nephrology, Huai’an First People’s Hospital, Nanjing Medical University, 6 Beijing Road West, Huai’an, 223300, Jiangsu, People’s Republic of China

    Guihua Wang, Lianhua Chen, Min Chen, Ling Zhuang & Liqin Zhang

  2. Department of Urology, Huai’an First People’s Hospital, Nanjing Medical University, 6 Beijing Road West, Huai’an, 223300, Jiangsu, People’s Republic of China

    Junsong Meng

Authors
  1. Guihua Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Lianhua Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Junsong Meng
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Min Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ling Zhuang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Liqin Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Lianhua Chen.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wang, G., Chen, L., Meng, J. et al. Overexpression of microRNA-100 predicts an unfavorable prognosis in renal cell carcinoma. Int Urol Nephrol 45, 373–379 (2013). https://doi.org/10.1007/s11255-012-0374-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11255-012-0374-y

Keywords

Search

Navigation